Search research articles
Contact Us
Filters
Showing results (31-40 of 40) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 40 results.
Cardiovascular Therapeutics
|
July 15, 2010
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy
Helena Vaverkova, Michel Farnier, Maurizio Averna, et al.
Medgenmed : Medscape General Medicine
|
December 22, 2005
LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD
James McKenney, Christie M Ballantyne, Theodore A Feldman, et al.
Diabetes & Vascular Disease Research
|
May 13, 2011
Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes
John R Guyton, D John Betteridge, Michel Farnier, et al.
Diabetes & Vascular Disease Research
|
August 24, 2011
Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome
Maurizio Averna, Luc Missault, Helena Vaverkova, et al.
Journal of Clinical Lipidology
|
November 24, 2011
Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study)
Jennifer G Robinson, Christie M Ballantyne, Willa Hsueh, et al.
Current Medical Research and Opinion
|
August 25, 2004
Efficacy and safety of simvastatin in Asian and non-Asian coronary heart disease patients: a comparison of the GOALLS and STATT studies
Dante Morales, Namsik Chung, Jun-Ren Zhu, et al.
Metabolic Syndrome and Related Disorders
|
March 29, 2008
Efficacy and safety of ezetimibe/simvastatin versus simvastatin monotherapy in hypercholesterolemic patients with metabolic syndrome
Theodore Feldman, Leiv Ose, Arvind Shah, et al.
Journal of Clinical Lipidology
|
February 5, 2011
Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes
Ruth S Weinstock, Ronald B Goldberg, John R Guyton, et al.
Diabetes Care
|
June 29, 2004
Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S)
Kalevi Pyörälä, Christie M Ballantyne, Barry Gumbiner, et al.
Annals of Hematology
|
April 25, 2024
Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice
Aleksander Chojecki, Danielle Boselli, Allison Dortilus, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 40) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 40 results.
Cardiovascular Therapeutics
|
July 15, 2010
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy
Helena Vaverkova, Michel Farnier, Maurizio Averna, et al.
Medgenmed : Medscape General Medicine
|
December 22, 2005
LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD
James McKenney, Christie M Ballantyne, Theodore A Feldman, et al.
Diabetes & Vascular Disease Research
|
May 13, 2011
Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes
John R Guyton, D John Betteridge, Michel Farnier, et al.
Diabetes & Vascular Disease Research
|
August 24, 2011
Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome
Maurizio Averna, Luc Missault, Helena Vaverkova, et al.
Journal of Clinical Lipidology
|
November 24, 2011
Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study)
Jennifer G Robinson, Christie M Ballantyne, Willa Hsueh, et al.
Current Medical Research and Opinion
|
August 25, 2004
Efficacy and safety of simvastatin in Asian and non-Asian coronary heart disease patients: a comparison of the GOALLS and STATT studies
Dante Morales, Namsik Chung, Jun-Ren Zhu, et al.
Metabolic Syndrome and Related Disorders
|
March 29, 2008
Efficacy and safety of ezetimibe/simvastatin versus simvastatin monotherapy in hypercholesterolemic patients with metabolic syndrome
Theodore Feldman, Leiv Ose, Arvind Shah, et al.
Journal of Clinical Lipidology
|
February 5, 2011
Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes
Ruth S Weinstock, Ronald B Goldberg, John R Guyton, et al.
Diabetes Care
|
June 29, 2004
Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S)
Kalevi Pyörälä, Christie M Ballantyne, Barry Gumbiner, et al.
Annals of Hematology
|
April 25, 2024
Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice
Aleksander Chojecki, Danielle Boselli, Allison Dortilus, et al.
Page
of 4